Shares in Sun Pharma, India's biggest drugmaker by value, fell as much as 6.4 percent on Thursday after the FDA's "import alert", which appeared on Wednesday on the agency's website.

An ‘import alert’ results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.

The Karkhadi plant makes both drug ingredients and formulations, according to Sun Pharma’s 2013 annual report.

The FDA action against Sun Pharma comes amid a rash of regulatory sanctions against Indian generic makers in the last year, triggering concerns about the quality of the medicines supplied by India's USD 14 billion drug industry to countries including United States, the biggest market.

The FDA has banned all the India plants of Ranbaxy Laboratories, India's No.1 drugmaker by sales, due to lapses in production quality. Rival Wockhardt has also been barred by regulators from exporting drugs from some of its plants to United States and United Kingdom.

India is second only to Canada as a drug exporter to the United States, where it supplies about 40 percent of generic and over-the-counter drugs.

JPN/Agencies

Latest News  from Business News Desk